Insulet (NASDAQ:PODD) Given New $366.00 Price Target at Raymond James Financial

by · The Cerbat Gem

Insulet (NASDAQ:PODD – Free Report) had its price target lifted by Raymond James Financial from $360.00 to $366.00 in a report released on Friday,MarketScreener reports. Raymond James Financial currently has an outperform rating on the medical instruments supplier’s stock.

PODD has been the topic of several other reports. Leerink Partners lifted their price target on shares of Insulet from $339.00 to $355.00 and gave the stock an “outperform” rating in a report on Tuesday, October 14th. Stifel Nicolaus began coverage on Insulet in a research note on Tuesday, October 21st. They set a “buy” rating and a $370.00 target price on the stock. Barclays upped their target price on Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research report on Wednesday. Canaccord Genuity Group raised their price target on Insulet from $353.00 to $399.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Finally, Royal Bank Of Canada boosted their price target on Insulet from $350.00 to $365.00 and gave the stock an “outperform” rating in a research note on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $370.76.

Read Our Latest Report on Insulet

Insulet Stock Down 1.1%

Insulet stock traded down $3.58 during trading hours on Friday, reaching $319.82. The stock had a trading volume of 677,166 shares, compared to its average volume of 721,278. The company has a market cap of $22.51 billion, a price-to-earnings ratio of 97.21, a PEG ratio of 2.64 and a beta of 1.39. The business’s 50 day moving average price is $325.06 and its 200-day moving average price is $309.40. Insulet has a 52 week low of $230.05 and a 52 week high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same period last year, the business earned $1.08 EPS. The company’s revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that Insulet will post 3.92 EPS for the current year.

Insider Activity

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The SEC filing for this sale provides additional information. 0.39% of the stock is currently owned by insiders.

Institutional Trading of Insulet

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after purchasing an additional 87,845 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Insulet by 3.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock valued at $603,211,000 after buying an additional 58,309 shares during the period. American Century Companies Inc. lifted its holdings in shares of Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after buying an additional 297,734 shares during the period. Groupama Asset Managment boosted its stake in shares of Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after buying an additional 3,759 shares during the last quarter. Finally, Norges Bank acquired a new stake in Insulet during the second quarter worth about $324,689,000.

Insulet Company Profile

(Get Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Featured Stories